S4: The LatAm-FINGERS Initiative: The First Non-Pharmacological Randomized Controlled Trial to Prevent Cognitive Decline Across Latin America
Gustavo E. Sevlever,Lucía Crivelli,Rosa Maria Salinas,Ana Charamelo,Carolina Delgado
DOI: https://doi.org/10.1017/s1041610224001029
IF: 7.191
2024-11-29
International Psychogeriatrics
Abstract:Overview: Gustavo E. Sevlever Approximately 40% of global dementia cases in high-income countries are attributed to potentially modifiable risk factors, whereas in Latin America, this figure rises to 56%. This difference underscores the importance of initiating preventive trials in the region. LatAm- FINGERS is the first non-pharmacological multicenter randomized clinical trial in Latin America, involving 12 countries: Argentina, Brazil, Bolivia, Chile, Colombia, Costa Rica, Ecuador, Mexico, Puerto Rico, the Dominican Republic, and Uruguay. The trial aims to prevent cognitive impairment through a multidomain lifestyle intervention. It evaluates the feasibility and efficacy of these interventions in enhancing cognitive function among 1,200 participants over two years. The lifestyle intervention, modeled after the Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER), encompasses nutrition, physical exercise, cardiovascular risk factor management, cognitive training, and socialization. Harmonization processes have ensured consistency with FINGER and the U.S. Study to Protect Brain Health through Lifestyle Intervention to Reduce Risk (U.S. POINTER) across Latin America. Since recruitment commenced in December 2021, 1,867 participants have been screened, with 1,186 enrolled. The cohort is predominantly female (73.8%), with an average age of 67.41 years, representing diverse ethnic backgrounds. LatAm-FINGERS has established the largest dataset on dementia risk in the region, evolving into a comprehensive database for cognitive, imaging, biomarker, and genetic research. It aims to promote collaborative efforts in dementia prevention across Latin America. In this session, we will provide an overview of the trial's Objectives and outcomes, the basis for the multidomain interventions, and describe the recruitment and adherence strategies implemented. We will conclude with results regarding the association of cardiovascular risk factors with social determinants of health. 1: Lucía Crivelli LatAm-FINGERS: Establishing Eligibility and Outcomes for Effective Research Across Latin America Objectives: LatAm-FINGERS is the first non-pharmacological, multicenter randomized clinical trial in Latin America, involving 12 countries and aiming to prevent cognitive impairment. The trial's primary Objectives is to assess the feasibility and efficacy of a multidomain lifestyle intervention in improving cognitive function among 1,200 participants over two years. Additionally, this study aims to evaluate the validity properties of cognitive outcomes within the LatAm-FINGERS cohort. Methods: To ensure consistency, the study employed harmonization processes with the original FINGER trial and the U.S. POINTER trial as part of the Worldwide FINGERS initiative. Eligibility criteria were standardized using normative z-scores. The Latin American Neuropsychological Battery (LatAm-NTB) was developed, including tests such as the Free and Cued Selective Reminding Test, Logical Memory, Digit Span, Stroop Test, Concept Shifting Test, Trail Making Test, Symbol Digit Modalities Test, and semantic and phonological fluency. A multivariate regression model was used to evaluate the validity of the LatAm-NTB. Results: Since recruitment began in December 2021, 1,186 participants have been enrolled. The mean age is 67.41 years (SD = 4.65), with an average educational level of 12.9 years (SD = 3.7) and an average Mini-Mental State Examination (MMSE) score of 27.2 (SD = 2.17). Women comprise 73.8% of the cohort. A multivariate regression model, which included sociodemographic variables, non-modifiable risk factors, and cardiovascular risk, was constructed to explain cognitive performance. This model demonstrated better fit parameters (BIC: 734.649, AIC: 793.661) compared to the reduced model (BIC: 1041.591, AIC: 1051.426). Higher education (β = 0.04, SE = 0.003, p < .001), younger age (β = –0.01, SE = 0.002, p < .001), and a lower Framingham Risk Score (β = –0.01, SE = 0.003, p < .001) were associated with better cognitive performance. Being male was not significantly associated with cognitive outcomes (β = –0.01, SE = 0.02, p = 0.57). Conclusions: Eligibility criteria were adequate to select the targeted population. The results suggest that the LatAm-NTB has promising validity indicators for assessing cognition in a follow- up clinical trial in Latin America. 2: Ana Charamelo Design and Harmonization of Interventions, barriers, and challenges Background: The Objectives of this analysis is to show how an intervention in Latin American lifestyles to prevent cognitive deterioration was initiated, its design, and what harmonization strategies were used, taking into account the multiculturalism of this population, constituted by 12 countries throughout the continent. It is the first randomized, multicenter, non- pharmacolog -Abstract Truncated-
psychiatry,geriatrics & gerontology,psychology, clinical,gerontology